8-K current report · filed Nov 3, 2026

ARDELYX, INC. (ARDX) 8-K Current Report: November 3, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2ARDX overview

Short answer

ARDELYX, INC. (ARDX) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Ardelyx announced financial results for the quarter ended September 30, 2026.

ARDELYX, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Ardelyx announced financial results for the quarter ended September 30, 2026
  • Full quarterly results and management commentary are provided in Exhibit 99.1
  • Results announcement gives investors updated visibility into quarterly operating performance and financial condition

Item 7.01 · Regulation FD Disclosure

  • Earnings presentation for quarter ended September 30, 2026 furnished as Exhibit 99.2
  • November 3, 2026 conference call covering quarterly financial results
  • Investor focus: presentation may provide management commentary and operating updates beyond reported figures

Item EX-99.1 · Exhibit EX-99.1

  • Q3 product revenue $125.5M, up 19%, led by IBSRELA revenue $96.3M, up 23%
  • XPHOZAH revenue $29.2M, up 7%, indicating slower growth than IBSRELA
  • Q3 net loss narrowed to $0.7M from $1.0M, while nine-month net loss reached $55.1M
  • Cash, equivalents and investments rose to $285.3M, supporting commercial expansion and ACCEL trial execution
  • ACCEL enrollment completed ahead of schedule, with topline data expected in the second half of 2027

Item EX-99.2 · Exhibit EX-99.2

  • Q3 product revenue $125.5M, up 19% YoY, with IBSRELA growth offsetting slower XPHOZAH expansion
  • IBSRELA revenue $96.3M, up 23% YoY, supporting long-term $1B annual revenue ambition
  • XPHOZAH revenue $29.2M, up 7% YoY, indicating continued momentum in dialysis hyperphosphatemia treatment
  • Net loss narrowed to $0.7M, while operating expenses rose 17% to $119.1M
  • FY2026 guidance reaffirmed: IBSRELA $350-$370M, XPHOZAH $110-$120M, operating expenses below $500M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ARDELYX, INC. 8-K filings

Get the next ARDX 8-K as it lands

Follow ARDX for push alerts, or ask the research agent what this filing means.